Windlas Biotech Limited has announced a board meeting to discuss the financial results for the quarter and half-year.

The company has completed dispatch of its 24th Annual General Meeting notice and Annual Report for FY 2024-25 to shareholders.

No material operational changes, business developments, new orders, or fines were reported.

The update focuses on compliance and corporate governance activities, with no immediate financial impact indicated.